Physician

Kishori Veerabhadrappa, M.D

According to 2025 Medicare claims, Kishori Veerabhadrappa, M.D (NPI: 1275824781) practices hematology/oncology in the Scranton--Wilkes-Barre, PA market, with the plurality of this provider's patient population coming from Lackawanna, PA. This provider's primary affiliated billing organization is HEMATOLOGY AND ONCOLOGY ASSOCIATES OF NORTHEASTERN PA, PC (NPI: 1164538724; TIN: 232137083) and primary practice location at 18512-3169. Veerabhadrappa is affiliated with the Keystone ACO (ACO ID: A1552), participating under the MSSP model.

Veerabhadrappa's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 881 traditional Medicare patients, billed 179,254 HCPCS/CPT codes, and received $3,495,534 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,693 prescription claims across 308 beneficiaries totaling $4,253,813 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 168 claims. Open Payments data shows 9 records totaling $225. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $983,517 to $3,495,534. Similarly, Part D prescription costs have moved sharply higher in recent years, from $358,452 to $4,253,813. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,591 to $563.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	689	86,803	$983,517
2016	652	142,242	$1,401,138
2017	652	133,681	$1,556,659
2018	710	182,120	$2,254,220
2019	821	202,278	$2,983,605
2020	805	182,552	$3,135,592
2021	804	142,454	$2,327,498
2022	896	202,353	$2,656,091
2023	882	175,673	$3,053,204
2024	881	179,254	$3,495,534

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	149	676	$358,452
2016	158	855	$581,648
2017	178	1,088	$1,238,733
2018	217	1,322	$1,574,745
2019	228	1,261	$1,314,038
2020	235	1,290	$1,588,115
2021	256	1,379	$2,515,225
2022	276	1,449	$2,933,550
2023	276	1,438	$2,513,485
2024	308	1,693	$4,253,813

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	160	$67,384
2016	N/R	110	$31,422
2017	N/R	82	$16,186
2018	N/R	158	$17,418
2019	N/R	129	$28,598
2020	N/R	85	$4,790
2021	N/R	137	$7,074
2022	12	169	$4,734
2023	N/R	152	$18,956
2024	N/R	168	$3,127

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	430	817	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	381	575	$59
82728	Ferritin (blood protein) level	378	791	$13
80053	Blood test, comprehensive group of blood chemicals	721	2,118	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	707	2,183	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	70	1,749	$794,155
Ibrance	Palbociclib	47	1,316	$738,622
Revlimid	Lenalidomide	25	679	$423,789
Kisqali	Ribociclib Succinate	18	504	$257,889
Calquence	Acalabrutinib Maleate	16	480	$239,971

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	31	$1,051
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	48	$866
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	39	$477
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	19	$376
J8520	Capecitabine, oral, 150 mg	N	N/R	31	$359

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	9	$225	SOBI, INC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kishori Veerabhadrappa, M.D?

Tedicare shows public-source Medicare data for Kishori Veerabhadrappa, M.D (NPI 1275824781), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kishori Veerabhadrappa, M.D have ACO affiliation data?

Kishori Veerabhadrappa, M.D is shown with ACO affiliation data for Keystone ACO (MSSP, ACO ID A1552).

What billing organization is linked to Kishori Veerabhadrappa, M.D?

Kishori Veerabhadrappa, M.D is linked to HEMATOLOGY AND ONCOLOGY ASSOCIATES OF NORTHEASTERN PA, PC (billing NPI 1164538724) in the available physician profile data.

Does Kishori Veerabhadrappa, M.D have Open Payments data?

Kishori Veerabhadrappa, M.D has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.